Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio (Nasdaq: VOR) announced inducement awards on May 1, 2026: 53,400 stock options and 11,350 RSUs granted to six newly hired employees under the Vor Biopharma 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) announced inducement awards on May 1, 2026: 53,400 stock options and 11,350 RSUs granted to six newly hired employees under the Vor Biopharma 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

Options have a 10-year term and an exercise price of $13.85 (closing price on grant date). Options vest 25% after 12 months, then monthly over 36 months; RSUs vest 25% after 12 months, then quarterly over 36 months, subject to continued employment.

Argus May 5 session

+5.51% close to close Open Argus

Details

News Market Reaction – VOR

On May 5, the first trading day after this news, VOR closed 5.51% above the previous close.

Data tracked by StockTitan Argus for the May 5 session.

Key Figures

Stock options granted: 53,400 shares RSUs granted: 11,350 shares New hires: 6 employees +5 more

Stock options granted

53,400 shares

Inducement grants to 6 new employees on May 1, 2026

RSUs granted

11,350 shares

Inducement grants to 6 new employees on May 1, 2026

New hires

6 employees

Recipients of options and RSUs under 2023 Inducement Plan

Option term

10 years

Term of inducement stock options granted May 1, 2026

Exercise price

$13.85 per share

Equal to closing price on May 1, 2026 grant date

Initial vesting cliff

25% after 12 months

Applies to both options and RSUs, subject to continued employment

Remaining option vesting

Monthly over 36 months

Post-cliff vesting schedule for stock options

Remaining RSU vesting

Quarterly over 36 months

Post-cliff vesting schedule for RSUs

Historical Context

5 past events · Latest: Apr 01

5 events

1. Apr 01

   Inducement grants

   24h Move

   +3.8%

   Announced inducement stock options and RSUs for nine new hires under 2023 plan.

2. Mar 30

   Earnings & update

   24h Move

   +1.5%

   Reported Q4/2025 results, strong cash position, and Phase 3 gMG timeline.

3. Mar 30

   Phase 3 trial start

   24h Move

   +1.5%

   Dosed first patient in global Phase 3 UPSTREAM SjD trial of telitacicept.

4. Mar 27

   Private placement

   24h Move

   +1.9%

   Announced $75M private placement to fund Phase 3 programs and corporate needs.

5. Mar 23

   Inducement grants

   24h Move

   -4.3%

   Disclosed prior inducement stock options and RSUs for new employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"stock options to purchase an aggregate of 53,400 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on May 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 53,400 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 11,350 shares of Vor Bio’s common stock to 6 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

The stock options have a ten-year term, and an exercise price of $13.85 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did Vor Bio (VOR) announce on May 1, 2026?

Vor Bio granted 53,400 stock options and 11,350 RSUs to six new hires. According to Vor Bio, the awards were made under the 2023 Inducement Plan as material inducements under Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and term for the VOR stock options granted May 1, 2026?

The stock options have a 10-year term with an exercise price of $13.85. According to Vor Bio, $13.85 equals the closing price of Vor Bio common stock on the grant date.

How do the VOR option and RSU vesting schedules work for the May 2026 grants?

Both awards vest over four years with 25% after 12 months. According to Vor Bio, options vest monthly over the next 36 months while RSUs vest quarterly over the next 36 months, subject to continued employment.

Under what plan were Vor Bio’s May 1, 2026 inducement awards granted?

The grants were made under the Vor Biopharma 2023 Inducement Plan. According to Vor Bio, the awards are subject to the Inducement Plan terms and separate award agreements covering the grants.

Why did Vor Bio (VOR) use Nasdaq Listing Rule 5635(c)(4) for these grants?

Vor Bio used Rule 5635(c)(4) to treat the grants as material inducements to employment. According to Vor Bio, that Nasdaq rule permits one-time inducement awards outside existing equity plans for new hires.